Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G CHAPUIS

Showing results (71-80 of 105) with videos related to

Pageof 11
Sort By:
The Journal of Experimental Medicine|June 1, 2016
Combined IL-21-primed polyclonal CTL plus CTLA4 blockade controls refractory metastatic melanoma in a patientAude G Chapuis, Sylvia M Lee, John A Thompson, et al.
Journal of Immunological Methods|December 31, 2020
Detection of engineered T cells in FFPE tissue by multiplex in situ hybridization and immunohistochemistryJocelyn H Wright, Li-Ya Huang, Stephanie Weaver, et al.
Biorxiv : the Preprint Server for Biology|September 30, 2024
Overcoming immune evasion from post-translational modification of a mutant KRAS epitope to achieve TCR-T cell-mediated antitumor activityJihoon William Lee, Emily Y Chen, Taylor Hu, et al.
AIDS (London, England)|September 21, 2000
Immunological and virological responses in HIV-1-infected adults at early stage of established infection treated with highly active antiretroviral therapyP A Bart, G P Rizzardi, G Tambussi, et al.
Cancer Immunology Research|March 18, 2020
Prevalent and Diverse Intratumoral Oncoprotein-Specific CD8<sup>+</sup> T Cells within Polyomavirus-Driven Merkel Cell CarcinomasLichen Jing, Mariliis Ott, Candice D Church, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 9, 2016
T-Cell Therapy Using Interleukin-21-Primed Cytotoxic T-Cell Lymphocytes Combined With Cytotoxic T-Cell Lymphocyte Antigen-4 Blockade Results in Long-Term Cell Persistence and Durable Tumor RegressionAude G Chapuis, Ilana M Roberts, John A Thompson, et al.
Cancer Immunology Research|January 17, 2014
Regression of metastatic Merkel cell carcinoma following transfer of polyomavirus-specific T cells and therapies capable of re-inducing HLA class-IAude G Chapuis, Olga K Afanasiev, Jayasri G Iyer, et al.
Science Translational Medicine|March 1, 2013
Transferred WT1-reactive CD8+ T cells can mediate antileukemic activity and persist in post-transplant patientsAude G Chapuis, Gunnar B Ragnarsson, Hieu N Nguyen, et al.
JCI Insight|May 8, 2024
MR1-restricted T cell clonotypes are associated with "resistance" to Mycobacterium tuberculosis infectionDeborah L Cross, Erik D Layton, Krystle Kq Yu, et al.
Journal for Immunotherapy of Cancer|February 4, 2026
Dysregulated expression of the tumor suppressor p14ARF in cancer provides an effective target for TCR-T cell therapeuticsThomas M Schmitt, Kelsey Furiya, Cheryl Black, et al.
Pageof 11

Showing results (71-80 of 105) with videos related to

Sort By:
Pageof 11
The Journal of Experimental Medicine|June 1, 2016
Combined IL-21-primed polyclonal CTL plus CTLA4 blockade controls refractory metastatic melanoma in a patientAude G Chapuis, Sylvia M Lee, John A Thompson, et al.
Journal of Immunological Methods|December 31, 2020
Detection of engineered T cells in FFPE tissue by multiplex in situ hybridization and immunohistochemistryJocelyn H Wright, Li-Ya Huang, Stephanie Weaver, et al.
Biorxiv : the Preprint Server for Biology|September 30, 2024
Overcoming immune evasion from post-translational modification of a mutant KRAS epitope to achieve TCR-T cell-mediated antitumor activityJihoon William Lee, Emily Y Chen, Taylor Hu, et al.
AIDS (London, England)|September 21, 2000
Immunological and virological responses in HIV-1-infected adults at early stage of established infection treated with highly active antiretroviral therapyP A Bart, G P Rizzardi, G Tambussi, et al.
Cancer Immunology Research|March 18, 2020
Prevalent and Diverse Intratumoral Oncoprotein-Specific CD8<sup>+</sup> T Cells within Polyomavirus-Driven Merkel Cell CarcinomasLichen Jing, Mariliis Ott, Candice D Church, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 9, 2016
T-Cell Therapy Using Interleukin-21-Primed Cytotoxic T-Cell Lymphocytes Combined With Cytotoxic T-Cell Lymphocyte Antigen-4 Blockade Results in Long-Term Cell Persistence and Durable Tumor RegressionAude G Chapuis, Ilana M Roberts, John A Thompson, et al.
Cancer Immunology Research|January 17, 2014
Regression of metastatic Merkel cell carcinoma following transfer of polyomavirus-specific T cells and therapies capable of re-inducing HLA class-IAude G Chapuis, Olga K Afanasiev, Jayasri G Iyer, et al.
Science Translational Medicine|March 1, 2013
Transferred WT1-reactive CD8+ T cells can mediate antileukemic activity and persist in post-transplant patientsAude G Chapuis, Gunnar B Ragnarsson, Hieu N Nguyen, et al.
JCI Insight|May 8, 2024
MR1-restricted T cell clonotypes are associated with "resistance" to Mycobacterium tuberculosis infectionDeborah L Cross, Erik D Layton, Krystle Kq Yu, et al.
Journal for Immunotherapy of Cancer|February 4, 2026
Dysregulated expression of the tumor suppressor p14ARF in cancer provides an effective target for TCR-T cell therapeuticsThomas M Schmitt, Kelsey Furiya, Cheryl Black, et al.
Pageof 11